Clinical Trial Search

Primary: Safety of Fuzheng Huayu Treatment in Chronic Hepatitis C Subjects Who Have Failed Prior Anti-HCV Therapy or Cannot Receive or Refused Interferon Based Therapy. — 55; 55…

Primary: Progression Free Survival (PFS) at the Time of Primary Results — 8.97; 11.30; 9.13; 13.63 Months — p=0.0010

Primary: Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular (CV) Death, Myocardial Infarction (MI), Stroke, or Urgent Coronary…

Primary: Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants — 3.9132 milliseconds (msec) — p=0.0161

Primary: Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1 — 0 participants

Primary: The Incidence of Perioperative Hypothermia — 39.8 Percentage of hypothermia participants

Primary: Pharmacokinetics: Dose-Normalized Area Under the Concentration Versus Time Curve of Docetaxel From Time Zero to Infinity [AUC(0-∞)] Following a Single Dose in Cycle 1…

Primary: Percentage of Subjects With an Immune Response Against Diphtheria, Tetanus and Pertussis, When Tdap is Concomitantly Administered With MenACWY-CRM Compared to Tdap Given…

Primary: Total Empa: Area Under the Curve 0 to Infinity (AUC0-∞) — 4708.33; 7462.74 nmol*h/L

Primary: Change From Baseline in HbA1c After 12 Weeks of Treatment. — 0.30; -0.42; -0.40; -0.65 percentage of HbA1c — p=<0.0001

Primary: Maximum Measured Concentration (Cmax) — 436; 1090 nmol/L

Primary: Change From Baseline in Total Urinary Glucose Excretion (UGE) — 74969.3; 62577.4; 57889.0; 23725.1 mg

Primary: Area Under the Curve 0 to Infinity (AUC0-∞) — 5190; 5340 nmol*h/L

Primary: Change in Glomerular Filtration Rate (GFR) After 8 Weeks of Treatment With Empagliflozin Under Controlled Conditions of Euglycaemia and Hyperglycaemia — -19.6; -33.4…

Primary: Successful Wingspan™ Stent Implantation (Access to the Lesion With the Stent, Accurate Deployment of the Stent Across the Target Lesion) — 78 patients w stent implanted